Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALX Oncology Holdings Inc. filings document a clinical-stage biotechnology issuer focused on cancer therapeutics and its Nasdaq-listed common stock. Recent 8-K reports furnish quarterly and annual financial results, corporate updates, clinical data releases for evorpacept and ALX2004, preliminary cash and investment information, and capital-structure disclosures tied to common stock and pre-funded warrant financing.
Proxy and governance filings describe board matters, executive compensation, equity awards, and shareholder voting items. Other material-event reports cover officer appointments, employment and compensatory arrangements, and amendments to the 2025 Inducement Equity Incentive Plan under Nasdaq inducement award rules.
ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026. Stockholders elected Class II directors Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P. to serve until the 2029 annual meeting, each continuing until a successor is elected and qualified.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, as described in the proxy statement. In addition, they ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
ALX Oncology Holdings Inc. investors affiliated with Lightstone Ventures filed Amendment No. 3 to update their ownership in the company’s common stock. The group now beneficially owns 2,942,525 shares, representing 2.2% of the common stock, based on 134,562,917 shares outstanding as of May 1, 2026.
The filing explains that the group ceased to be beneficial owners of more than five percent of ALX Oncology’s common stock on or about February 2, 2026. This change resulted from dilution due to the issuer’s issuance of additional shares, not from any purchases or sales by the reporting persons, and no transactions occurred in the prior sixty days.
Redmile Group, LLC and related filers reported beneficial ownership of ALX Oncology common stock. The filing states Redmile Group and Jeremy C. Green beneficially own 9,214,188 shares representing 6.8%, and Redmile Biopharma Investments III, L.P. owns 5,267,838 shares representing 3.9%. The percentages are calculated using 134,540,741 shares outstanding as of March 31, 2026 plus 1,250,000 shares issuable upon exercise of warrants. The filing notes the Warrants are subject to a 9.99% beneficial ownership limitation and that Redmile and Mr. Green disclaim beneficial ownership except to the extent of any pecuniary interest.
ALX Oncology Holdings Inc has a Schedule 13G/A amendment reporting that HBM Healthcare Investments (Cayman) Ltd. beneficially owns 8,590,692 shares of common stock, representing approximately 6.5% of the outstanding common stock. The filing states this ownership is calculated using 131,608,278 shares outstanding as of March 2, 2026. Voting and investment power over these shares is exercised by the reporting person’s board of directors, and the amendment is signed by Jean-Marc LeSieur on May 15, 2026.
ALX Oncology Holdings Inc. reported a narrower net loss of $17.9 million for the three months ended March 31, 2026, compared with $30.8 million a year earlier, as it reduced spending while advancing its cancer pipeline.
Research and development expenses fell to $13.6 million and general and administrative costs to $5.4 million, largely due to a 2025 workforce reduction and pipeline prioritization. The company remains a clinical‑stage biotech focused on its CD47 blocker evorpacept and EGFR‑targeted ADC ALX2004, with multiple ongoing and planned trials in solid tumors and blood cancers.
ALX Oncology strengthened its balance sheet through a February 2026 equity financing, ending the quarter with $169.1 million in cash, cash equivalents and investments and an accumulated deficit of $740.7 million. Management expects these resources to fund operations for at least 12 months while it continues development and regulatory activities.
ALX Oncology Holdings Inc. reported first quarter 2026 results showing a significantly narrower loss while advancing its cancer pipeline. GAAP net loss was $17.9 million, or $0.17 per share, compared with $30.8 million, or $0.58 per share, a year earlier. Non-GAAP net loss improved to $15.4 million from $25.5 million.
Research and development expenses fell to $13.6 million from $23.9 million, and general and administrative costs declined to $5.4 million from $7.9 million, mainly due to prior workforce reductions and pipeline prioritization. Cash, cash equivalents and investments totaled $169.1 million as of March 31, 2026, and the company expects this to fund operations through the first half of 2028.
Clinically, exploratory Phase 1b/2 data for CD47-inhibitor evorpacept plus zanidatamab in heavily pre-treated HER2-positive metastatic breast cancer showed a confirmed objective response rate of 60% and median progression-free survival of 8.3 months in centrally confirmed HER2-positive patients. All patients with HER2-positive disease and high CD47 expression responded, with a median duration of response of 20.2 months. The Phase 2 ASPEN-09-Breast trial remains on track for topline data in mid-2027, and the Phase 1 trial of EGFR-targeted ADC ALX2004 continues toward safety data in the second half of 2026.
ALX Oncology Holdings Inc. ownership update: three Millennium-related filers and Integrated Core Strategies report shared beneficial interests in ALX Oncology common stock totaling reported holdings of 730,528 shares (0.5%) for Integrated Core Strategies and 1,988,559 shares (1.5%) for each of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
The filing is a Schedule 13G/A amendment that attaches a Joint Filing Agreement dated April 27, 2026 and explains the securities are held by entities subject to voting or investment discretion by Millennium-affiliated managers; the filing does not admit beneficial ownership by the reporting parties.
ALX Oncology Holdings Inc. is holding its 2026 annual meeting of stockholders as a virtual-only webcast on June 10, 2026 at 1:00 p.m. Pacific Time. Stockholders of record as of April 15, 2026, when 134,559,917 common shares were outstanding, may attend online, submit questions and vote.
Investors will vote on electing three Class III directors until 2029, an advisory “say‑on‑pay” approval of named executive officer compensation, and ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The proxy also outlines board structure, director independence, committee roles, executive compensation philosophy and how to submit future stockholder proposals or director nominations.
ALX Oncology Holdings Inc. reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options covering 800,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.
According to the vesting terms, one-fourth of the options vest on April 13, 2027 and the remaining options vest in equal monthly installments over the following three years. After this grant, Knight holds 800,000 stock options directly.